Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing

International Journal of Antimicrobial Agents

Volumn 25, Issue 4, 2005, Pages 302-307

  Stout, Janet E ^a,b   Sens, Kelly ^a,b   Mietzner, Sue ^a,b   Obman, Asia ^a,b   Yu, Victor L ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Ketolides; Legionella pneumophila; Macrolides; Quinolones; Susceptibility

Indexed keywords

AZITHROMYCIN; CETHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; ERYTHROMYCIN; GEMIFLOXACIN; GREPAFLOXACIN; KETOLIDE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; QUINOLONE DERIVATIVE; TELITHROMYCIN; TROVAFLOXACIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DILUTION; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SENSITIVITY; IN VITRO STUDY; INTERMETHOD COMPARISON; INTRACELLULAR KILLING; LEGIONELLA PNEUMOPHILA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SEROTYPING; STATISTICAL SIGNIFICANCE;

EID: 15244362495     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.08.019     Document Type: Article

References (27)

1. M. Sabria, and V.L. Yu Legionella pneumophila V.L. Yu R. Weber D. Raoult Antimicrobial therapy and vaccines 2nd ed. 2002 Apple Trees Productions New York 395 417
2. V.L. Yu, R.N. Greenberg, and N. Zadeikis Levofloxacin efficacy in the treatment of community-acquired legionellosis Chest 125 2004 2135 2139
3. M.R. Hammerschlag, P.M. Roblin, and C.M. Bebear Activity of telithromycin, a new ketolide antibacterial against atypical and intracellular respiratory tract pathogens J Antimicrob Chemother 48 2001 25 31
4. P.M. Roblin, A. Kutlin, T. Reznick, and M.R. Hammerschlag Activity of grepafloxacin and other fluoroquinolones against recent clinical isolates of Chlamydia pneumoniae Int J Antimicrob Agent 12 1999 181 184
5. K.B. Waites, G.H. Cassell, K.C. Canupp, and P.B. Fernandez In vitro susceptibility of mycoplasmas to new macrolides and aryl-fluoroquinolones Antimicrob Agents Chemother 32 1998 1500 1502
6. National Committee for Clinical Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5 2002 National Committee for Clinical Laboratory Standards Wayne, PA
7. D.M. Liebers, A.L. Baltch, R.P. Smith, M.C. Hammer, and J.V. Conroy Susceptibility of Legionella pneumophila to eight antimicrobial agents including four macrolides under different assay conditions J Antimicrob Chemother 23 1989 37 41
8. J.E. Stout, B. Arnold, and V.L. Yu Comparative activity of ciprofloxacin, ofloxacin, levofloxacin, and erythromycin against Legionella species by broth microdilution and intracellular susceptibility testing in HL-60 cells Diagn Microbiol Infect Dis 30 1998 37 43
9. J.E. Stout, B. Arnold, and V.L. Yu Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin/dalfopristin and erythromycin against Legionella species by intracellular susceptibility testing in HL-60 cells J Antimicrob Chemother 41 1998 289 291
10. J. DuBois, and C. St. Pierre Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp J Antimicrob Chemother 45 2000 41 46
11. J.A.A. Hoogkamp-Korstanje In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infections J Antimicrob Chemother 40 1997 427 431
12. S.J. Martin, S.L. Pendland, C. Chen, P. Schreckenberger, and L.H. Danziger In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates of Legionella Antimicrob Agents Chemother 40 1996 1419 1421
13. P.H. Edelstein, and M.A. Edelstein In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs and use of the drugs to treat guinea pigs with Legionella pneumophila pneumonia Antimicrob Agents Chemother 43 1999 90 95
14. J. Garcia-de-Lomas, E. Millas, and M.A. Lazaro A comparative study on the efficacy of the new quinolone alatrofloxacin in the treatment of experimental legionellosis in guinea pigs Eur J Clin Microbiol Infect Dis 17 1998 420 423
15. D. Jonas, I. Engels, F.D. Daschner, and U. Frank The effect of azithromycin on intracellular Legionella pneumophila in the Mono Mac 6 cell line at serum concentrations attainable in vivo J Antimicrob Chemother 46 2000 385 390
16. R. Jung, L.H. Danziger, and S.L. Pendland Intracellular activity of ABT-773 and other antimicrobial agents against Legionella pneumophila J Antimicrob Chemother 49 2002 857 861
17. J.A. Ramirez, J.T. Summersgill, R.D. Miller, T.L. Myers, and M.J. Ruff Comparative study of the bactericidal activity of ampicillin/sulbactam and erythromycin against intracellular Legionella pneumophila J Antimicrob Chemother 32 1993 93 99
18. H. Takemura, H. Yamamoto, and H. Kunishima Evaluation of human monocytic cell line THP-1 model for the intracellular activities of antimicrobial agents against Legionella pneumophila J Antimicrob Chemother 46 2000 589 594
19. A. Walz, T. Nichterlein, and H. Hof Excellent activity of newer quinolones on Legionella pneumophila in J774 macrophages Zbl Bakt 285 1997 431 439
20. A. Marra, M.A. Horwitz, and H.A. Shuman The HL-60 model for the interaction of human macrophages with the Legionnaires' disease bacterium J Immunol 144 1990 2738 2744
21. M. Watanabe, Y. Shimamoto, and S. Yoshida Intracellular multiplication of Legionella pneumophila in HL-60 cells differentiated by 1,25-dihydroxy-vitamin D and the effect of interferon-gamma J Leuk Biol 54 1993 40 46
22. P.H. Edelstein, T. Shinzatao, E. Doyle, and M.A. Edelstein In vitro activity of gemifloxacin (SB-265805, LB 20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia Antimicrob Agents Chemother 45 2001 2204 2209
23. A.L. Baltch, R.P. Smith, W.J. Franke, and P.B. Mickelsen Antibacterial effect of telithromycin (HMR 3647) and comparative antibiotics against intracellular Legionella pneumophila J Antimicrob Chemother 46 2000 51 55
24. I.A. Critchley, M.E. Jones, and P.D. Heize In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae from North America and Europe Clin Microbiol Infect 8 2002 214 221
25. T.M. File, J. Segreti, and L. Dunbar A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in the treatment of adults with community-acquired pneumonia Antimicrob Agents Chemother 41 1997 1965 1972
26. J. Lorenz Clinical efficacy of new antibacterial therapies in at-risk populations J Infect 44 Suppl. A 2002 25 30
27. C. Carbon, S. Moola, I. Velancsics, B. Leroy, M. Rangaraju, and P. Decosta Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia Clin Microbiol Infect 9 2003 691 703